Understanding how mitochondrial networks affect treatment response in advanced lung cancer
Investigating mitochondrial networks as a critical determinant of response to antibody drug conjugates in advanced NSCLC
This study is looking at how the tiny energy factories in your cells, called mitochondria, might affect how well patients with advanced lung cancer respond to new targeted treatments, helping to find out why some people do better than others and paving the way for more personalized care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11132193 on NIH RePORTER |
What this research studies
This research investigates the role of mitochondrial networks in determining how well patients with advanced non-small cell lung cancer (NSCLC) respond to new antibody drug conjugates (ADCs). The study focuses on three specific ADCs that have shown promise after standard therapies have failed. By examining the biological mechanisms behind these treatments, the research aims to identify why some patients benefit while others do not. This could lead to more personalized treatment strategies for patients with advanced lung cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced or metastatic non-small cell lung cancer who have not responded to standard treatments.
Not a fit: Patients with early-stage lung cancer or those who have not yet undergone standard therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with advanced lung cancer, potentially increasing their chances of response to therapy.
How similar studies have performed: Other research has shown promising results with similar approaches in understanding treatment responses in cancer, indicating that this area of investigation is both relevant and potentially impactful.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Lisberg, Aaron Elliott — University of California Los Angeles
- Study coordinator: Lisberg, Aaron Elliott
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.